Celcuity Inc. has released a corporate presentation highlighting their progress in cancer treatment, focusing on the PI3K/AKT/mTOR pathway. The presentation details the efficacy of gedatolisib in treating HR+/HER2- advanced breast cancer. Notably, the gedatolisib triplet and doublet therapies demonstrated significant improvement in median progression-free survival compared to fulvestrant alone. The company is currently enrolling patients for a Phase 3 study in first-line HR+/HER2- advanced breast cancer and conducting a Phase 1b/2 trial in second-line metastatic castration-resistant prostate cancer. Celcuity emphasizes the potential of PAM pathway inhibitors in oncology, targeting a large patient population in the US, Europe, and Japan. You can access the full presentation through the link below.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。